CJC 1295 vs Sermorelin: How the Two GHRH Peptides Differ
CJC 1295 vs sermorelin is a contrast of minutes and days: a 2026 review lists sermorelin's disappearance half-time at about 4.3 minutes, while a 2006 trial in healthy adults estimated the half-life of CJC-1295 at 5.8 to 8.1 days. Both are lab-made copies of GHRH, the signal that tells the pituitary gland to make growth hormone. Sermorelin formulations were FDA approved in 1990 and 1997, to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test how well the pituitary releases growth hormone. A 2026 review says neither form of CJC-1295 is approved by the FDA or EMA. No study has tested the two head to head, or together, in people.
Sources: Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg; USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema
Short answer
- Are they the same kind of peptide?
- Yes, in broad terms. Both copy GHRH. Sermorelin is a 29 amino acid copy. CJC-1295 is a long-acting copy built to stay in the blood for days.
- Which one is better?
- No one can say from the evidence. We found no human trial that compared them, in PubMed or ClinicalTrials.gov.
- Can they be used together?
- No study has tested the pair. That question is unanswered by research.
- Which has an approval record?
- Sermorelin, from 1990, to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function. CJC-1295 has never been approved by the FDA or EMA, per a 2026 review.
Sources: Review: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. August 1999. PMID 18031173. Supports: 29 amino acid analogue, shortest peptide with full GHRH activity; 30 microg/kg bedtime dose in some prepubertal children; flushing and injection site pain most common; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg; USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema; Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue
CJC 1295 vs Sermorelin Side by Side
The two share a target, the GHRH receptor system, but differ in how long they last, how much human data they have and whether they were ever approved. This table sets the records side by side.
| Feature | CJC-1295 | Sermorelin |
|---|---|---|
| What it is | A long-acting lab-made analog of GHRH (2006 trial title) | A 29 amino acid lab-made analogue of GHRH (1999 review) |
| How long it stays | Half-life 5.8 to 8.1 days (2006 trial) | Disappearance half-time about 4.3 minutes (2026 review) |
| Effect of one shot | Growth hormone up 2 to 10 fold for 6 days or more | Not measured in our sources |
| Forms | With DAC and without DAC; the no-DAC form has almost no human research | One peptide |
| FDA status | Neither form approved by FDA or EMA (2026 review) | Formulations approved in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function |
| Main human records | Two 2006 studies in healthy adults | A 1999 review of use in children |
| Side effects on record | FDA notes serious events: raised heart rate, vasodilatory reaction | Facial flushing and injection site pain (children) |
| Sport status | GHRH analogs prohibited by WADA | Prohibited, per USADA |
The table compares records from different studies. The sermorelin data come mostly from children. The CJC-1295 data come from healthy adults. So the two columns are not a fair contest, and no single trial stands behind them.
Sources: Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg; Human study: Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, December 2006. PMID 17018654. Supports: basal (trough) GH up 7.5 fold; pulses persisted; Review: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. August 1999. PMID 18031173. Supports: 29 amino acid analogue, shortest peptide with full GHRH activity; 30 microg/kg bedtime dose in some prepubertal children; flushing and injection site pain most common; Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue; USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema; FDA safety page: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, US FDA (2026, retrieved October 2026). Supports: the CJC-1295 entry, serious adverse events including increased heart rate and systemic vasodilatory reaction; Doping control study: Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. 15 January 2026. PMID 41138283. Supports: GHRH and its synthetic analogs are prohibited by WADA
Is Sermorelin Similar to CJC-1295?
Yes in what they copy, no in how long they work. Both are analogs of growth hormone-releasing hormone (GHRH), but sermorelin is short acting and CJC-1295 was designed to be long acting.
What GHRH does
GHRH is a hormone the body makes. It tells the pituitary gland, a small gland under the brain, to release growth hormone. USADA describes sermorelin as a synthetic peptide that mimics the action of GHRH. It says sermorelin stimulates the pituitary to increase the body's own production of growth hormone. So sermorelin does not add growth hormone from outside. It asks the body to make more.
Sermorelin: the shortest working piece
A 1999 review calls sermorelin a 29 amino acid analogue of human GHRH. Amino acids are the building blocks of peptides. The review says sermorelin is the shortest synthetic peptide that keeps the full biological activity of GHRH. In plain words, it is the smallest lab-made piece of the hormone that still does the whole job.
CJC-1295: the long-acting copy
The 2006 trial in healthy adults calls CJC-1295 a long-acting analog of GH-releasing hormone. Its design adds a part that lets it hold on in the blood for days, explained in the DAC section below. That is the main practical gap between the two. More detail is in our sermorelin profile and CJC-1295 with DAC profile.
Sources: USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema; Review: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. August 1999. PMID 18031173. Supports: 29 amino acid analogue, shortest peptide with full GHRH activity; 30 microg/kg bedtime dose in some prepubertal children; flushing and injection site pain most common; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg
Minutes vs Days: How Long Each One Lasts
Sermorelin clears from the blood in minutes, and one CJC-1295 shot kept growth hormone raised for 6 days or more. That gap, more than anything else, separates the two.
Half-life is the time it takes for half of a drug to leave the blood. A 2026 review lists sermorelin as short acting, with a disappearance half-time of about 4.3 minutes, plus or minus 1.4 minutes. The 2006 CJC-1295 trial estimated a half-life of 5.8 to 8.1 days. On these figures, the CJC-1295 half-life is roughly 2,000 times longer or more.
| Time after one shot | CJC-1295 | Sermorelin |
|---|---|---|
| Minutes | Still in the blood (half-life is measured in days) | About half gone in roughly 4.3 minutes |
| 6 days | Growth hormone still 2 to 10 fold higher than before | No data in our sources |
| 9 to 11 days | IGF-I still 1.5 to 3 fold higher than before | No data in our sources |
What one CJC-1295 shot did
In the 2006 trial, healthy adults got a single injection. Average growth hormone in the blood rose 2 to 10 fold, and stayed up for 6 days or more. Average IGF-I rose 1.5 to 3 fold and stayed up for 9 to 11 days. IGF-I is a growth factor the liver makes when growth hormone rises. The bigger the dose, the bigger the rise.
The second 2006 study
A second study looked at the pattern of growth hormone release. The body normally releases growth hormone in pulses, not a steady stream. With CJC-1295, the baseline level between pulses (the trough) rose 7.5 fold. The paper's title reports that the pulses still happened during this constant push. These are hormone readings. Neither study measured muscle, fat or how people felt.
Sources: Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg; Human study: Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, December 2006. PMID 17018654. Supports: basal (trough) GH up 7.5 fold; pulses persisted
CJC-1295 With DAC and Without DAC
Two forms are sold off-label, one with a drug-affinity complex (DAC) and one without, and a 2026 review says the form without DAC has essentially no peer-reviewed human data. This matters when comparing anything to sermorelin.
The review explains what DAC does. It lets the peptide bind to albumin, a common protein in the blood. That markedly lengthens exposure and gives a more lasting effect after a single dose. This is why the long-acting form lasts days rather than minutes.
The review says CJC-1295 without DAC remains essentially uncharacterised in the peer-reviewed human literature. So the day-long numbers on this page come from the long-acting analog in the 2006 trials. They should not be read as data for the form without DAC. See our CJC-1295 without DAC profile for that form.
Sources: Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg
Approval History: Sermorelin Has One, CJC-1295 Does Not
Sermorelin formulations were approved by the FDA in 1990 and 1997, to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test how well the pituitary releases growth hormone, per USADA. A 2026 review says neither CJC-1295 variant is approved as a therapeutic agent by major regulators such as the FDA or EMA.
Sermorelin
USADA says the two approvals were for idiopathic growth hormone deficiency in children with growth failure, or for testing how well the pituitary gland's cells can release growth hormone. Idiopathic means the cause is unknown. The 2026 review adds a later note about Geref, the sermorelin product it discusses. It says the FDA determined that Geref was not withdrawn for reasons of safety or effectiveness. We found no current FDA label for sermorelin in openFDA.
CJC-1295
CJC-1295 has no approval for any use. The FDA lists it on its page of bulk drug substances that may present significant safety risks in compounding (pharmacy mixing). There, the FDA says it has identified serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, meaning blood vessels widening across the body. The one GHRH analogue with a current FDA-approved use is tesamorelin. See tesamorelin vs sermorelin for that comparison.
Sources: USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema; Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue; FDA safety page: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, US FDA (2026, retrieved October 2026). Supports: the CJC-1295 entry, serious adverse events including increased heart rate and systemic vasodilatory reaction
Which Is Better, Sermorelin or CJC-1295?
No study answers this. We searched PubMed for sermorelin and CJC-1295 together and found only doping test papers and reviews, not a trial comparing them.
The same is true for "CJC-1295 ipamorelin" versus sermorelin. No human trial has compared them. Ipamorelin works on a different receptor, the ghrelin receptor, and we cover it in sermorelin vs ipamorelin and tesamorelin vs ipamorelin. This page sticks to the two GHRH peptides.
What the records can say is how much is known about each. Sermorelin has an approval history in children and a 1999 review of that use. CJC-1295 has two 2006 studies of hormone levels in healthy adults. Neither has a trial of body composition, recovery or performance in our sources.
People also ask which peptide is better than sermorelin. A 2026 review calls tesamorelin the most comprehensively characterised GHRH analogue from a regulatory and clinical trial view, backed by an FDA-approved indication. That ranks the evidence, not the result for any one person. No official source picks a peptide for an individual.
Sources: Review: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. August 1999. PMID 18031173. Supports: 29 amino acid analogue, shortest peptide with full GHRH activity; 30 microg/kg bedtime dose in some prepubertal children; flushing and injection site pain most common; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg; Human study: Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, December 2006. PMID 17018654. Supports: basal (trough) GH up 7.5 fold; pulses persisted; Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue
Can Sermorelin and CJC-1295 Be Taken Together?
Research does not answer this. We found no study of the combination in PubMed or ClinicalTrials.gov, so there is no data on how the two act together, or on the safety of the pair.
ClinicalTrials.gov lists one 2005 phase 2 CJC-1295 trial in people with HIV. It is marked terminated, with no results posted, and it did not include sermorelin. Both peptides copy the same hormone signal, so any claim about stacking them would be a guess. The 2026 review also says neither CJC-1295 form is FDA or EMA approved.
Side Effects and Safety
For sermorelin, a 1999 review reports facial flushing and injection site pain as the most common side effects. For CJC-1295, the FDA says it has identified serious adverse events, including increased heart rate and a systemic vasodilatory reaction.
Sermorelin
The 1999 review says transient facial flushing and pain at the injection site were the most commonly reported adverse events. Transient means it passed. Those reports came from use in children. USADA adds that many users report swelling and edema, which is fluid build-up, in the arms, legs and face.
CJC-1295
The authors of the 2006 trial called CJC-1295 safe and relatively well tolerated in healthy adults, mostly at the two lower doses listed below. The FDA view, from its compounding safety page, is the serious adverse events noted above. Our CJC-1295 side effects guide covers this in more depth.
CJC-1295 is long acting. The 2006 trial measured raised growth hormone for 6 days or more after a single shot, against minutes for sermorelin.
Sources: Review: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. August 1999. PMID 18031173. Supports: 29 amino acid analogue, shortest peptide with full GHRH activity; 30 microg/kg bedtime dose in some prepubertal children; flushing and injection site pain most common; USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg; FDA safety page: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, US FDA (2026, retrieved October 2026). Supports: the CJC-1295 entry, serious adverse events including increased heart rate and systemic vasodilatory reaction
Doses on Record
Both figures below are by body weight and come from research records, not a current label: sermorelin from a 1999 review of children, CJC-1295 from a 2006 trial in healthy adults.
The 1999 sermorelin review (PMID 18031173) reports:
Sermorelin: 30 mcg/kg body weight, injected under the skin once daily at bedtime (some prepubertal children with growth hormone deficiency; limited data)
Disclaimer: this is a historical dose in children from a 1999 review. It is not label information for adults and not a recommendation. Dose decisions belong with a licensed clinician.
The 2006 CJC-1295 trial (PMID 16352683) reports it was best tolerated at:
CJC-1295: 30 or 60 mcg/kg (single injection, healthy adults)
Disclaimer: these are trial doses of an unapproved compound. They are not label information and not a recommendation. Dose decisions belong with a licensed clinician.
For the unit math only, the CJC-1295 calculator shows how a dose converts to syringe units.
Sources: Review: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. August 1999. PMID 18031173. Supports: 29 amino acid analogue, shortest peptide with full GHRH activity; 30 microg/kg bedtime dose in some prepubertal children; flushing and injection site pain most common; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg
Sport and Drug Testing
Both are banned for tested athletes. USADA says sermorelin is prohibited because of its ability to enhance muscle growth, endurance and recovery by boosting the body's own growth hormone.
A 2026 doping lab paper says GHRH and its synthetic analogs are performance-enhancing substances and are prohibited by the World Anti-Doping Agency (WADA). That paper is about finding these peptides in urine. Sermorelin and CJC-1295 are both GHRH analogs. More on testing in do peptides show up on drug tests.
Sources: USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema; Doping control study: Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. 15 January 2026. PMID 41138283. Supports: GHRH and its synthetic analogs are prohibited by WADA
Common Questions
Is Sermorelin similar to CJC?+
Partly. Both are lab-made copies of GHRH, the signal that tells the pituitary gland to make growth hormone. The big difference is time. A 2026 review gives sermorelin a disappearance half-time of about 4.3 minutes, the point when about half has left the blood. CJC-1295 had a half-life of 5.8 to 8.1 days in a 2006 trial.
Which is better for me, Sermorelin or CJC-1295 Ipamorelin?+
No study can answer that. We found no human trial comparing sermorelin with CJC-1295, alone or with ipamorelin. No official source says one is better for any person. That choice belongs with a licensed clinician who knows your health.
Which peptide is better than Sermorelin?+
No trial shows any peptide is better than sermorelin. A 2026 review says tesamorelin is the most studied GHRH analogue from a regulatory and trial view, and it has an FDA-approved use. That is a statement about the evidence, not about results.
Can I take Sermorelin and CJC-1295 together?+
This is not answered by research. We found no study of the two together in PubMed or ClinicalTrials.gov. A 2026 review says neither CJC-1295 form is FDA or EMA approved, and both peptides are banned in sport.
Is CJC-1295 FDA approved?+
No. A 2026 review says neither CJC-1295 variant is approved as a therapeutic agent by major regulators such as the FDA or EMA. The FDA says it has identified serious adverse events with CJC-1295, including increased heart rate.
How long does CJC-1295 last compared with sermorelin?+
Days versus minutes. After one CJC-1295 shot in a 2006 trial, growth hormone stayed 2 to 10 fold higher for 6 days or more. Sermorelin has a disappearance half-time of about 4.3 minutes, per a 2026 review.
Are sermorelin and CJC-1295 banned in sport?+
Yes. USADA says sermorelin is prohibited. A 2026 doping lab paper says GHRH and its synthetic analogs are prohibited by WADA, and CJC-1295 is described as a GHRH analog.
Sources: Review: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 18 June 2026. PMC13322892 (PMID 42395176). Supports: sermorelin half-time about 4.3 minutes; Geref not withdrawn for safety or effectiveness; CJC-1295 with and without DAC; DAC binds albumin; no-DAC form uncharacterised in humans; neither variant approved by FDA or EMA; tesamorelin the most characterised GHRH analogue; Human trial (healthy adults): Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, March 2006. PMID 16352683. Supports: GH up 2 to 10 fold for 6 days or more, IGF-I up 1.5 to 3 fold for 9 to 11 days, half-life 5.8 to 8.1 days, tolerability at 30 or 60 microg/kg; USADA web page: What Should Athletes Know About Sermorelin? US Anti-Doping Agency, Spirit of Sport series (2025, retrieved October 2026). Supports: sermorelin copies GHRH and prompts the pituitary; FDA approvals in 1990 and 1997 to treat idiopathic (no known cause) growth hormone deficiency in children with growth failure or to test pituitary function; prohibited in sport; users report swelling and edema; FDA safety page: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, US FDA (2026, retrieved October 2026). Supports: the CJC-1295 entry, serious adverse events including increased heart rate and systemic vasodilatory reaction; Doping control study: Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. 15 January 2026. PMID 41138283. Supports: GHRH and its synthetic analogs are prohibited by WADA
Related reading
Tesamorelin vs Sermorelin
Two GHRH analogs, one with an FDA label
Sermorelin vs Ipamorelin
GHRH analog vs ghrelin mimic
CJC-1295 Side Effects
What studies and the FDA report
Sermorelin
Full profile of the short-acting GHRH analog
CJC-1295 With DAC
Full profile of the long-acting form
HGH vs Peptides
Growth hormone and the peptides said to act on it
This guide is for educational purposes only and is not medical advice. It describes what published studies, USADA and the FDA report about CJC-1295 and sermorelin. It is not an endorsement or an instruction to use any compound. CJC-1295 is not an approved medicine. Talk to a qualified healthcare professional before making any decision about your health.